Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Neuron23 launches clinical trial for NEU-723 in Parkinson’s with companion diagnostic in development

By Brian Buntz | February 7, 2023

Neuron23South San Francisco–based Neuron23 has started the first-in-human Phase 1 trial of NEU-723 for the treatment of Parkinson’s disease. NEU-723 is a highly potent and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor. This clinical trial will evaluate the safety, tolerability and pharmacokinetics of NEU-723 in healthy volunteers.

A targeted approach

The company has also collaborated with the diagnostics firm Qiagen to develop a companion diagnostic to identify a sub-population of Parkinson’s disease patients likely to respond to LRRK2 inhibitors.

“We wanted to try to narrow the population to those who would benefit and respond,” said Nancy Stagliano, chief executive officer of Neuron23. “So we built a machine learning model that can predict if patients respond to this drug or not.”

Stagliano says the targeted approach is “a big differentiator.” “To our knowledge, no one else has done this in neurodegenerative disease,” she said.

The company is advancing programs against TYK2, a JAK family protein that plays a role in pathological immune signaling. Parkinson’s disease is a brain disorder that causes unintended movements and worsens over time leading to difficulty in walking and talking. It is usually diagnosed based on medical history and neurological examination. There is currently no cure or disease-modifying therapies for the condition.

NEU-723 is the first of Neuron23’s programs to enter clinical development.

Disease-modifying potential

Neuron23 believes NEU-723 has strong disease-modifying potential and a higher therapeutic index compared to other candidates in development based on preclinical studies.

This randomized, double-blind, placebo-controlled, single-ascending dose, multiple-ascending dose, single-site clinical trial will evaluate the safety, tolerability, and pharmacokinetics of NEU-723 in adult healthy volunteers.

In addition to NEU-723, Neuron23 has several other LRRK2 candidates in its pipeline, including NEU-411 for Parkinson’s disease, which is set to enter the clinic in 2023. The company is also advancing brain-penetrant and peripherally restricted programs against TYK2, a JAK family protein involved in pathological immune signaling.

Researchers have linked the genetics for LRRK2 to not just Parkinson’s, but to some incidence of inflammatory bowel disease (IBD) as well. “Right now, we are not prioritizing [IBD], but there are interesting genetics in gut diseases that lead to increased risk,” Stagliano said. “You can imagine a systemic opportunity that can be used for those indications, and that’s something we have on the back burner, and we’re considering where to put it in our pipeline.”


Filed Under: clinical trials, Drug Discovery, Neurological Disease, Uncategorized
Tagged With: NEU-723
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
From 1.5% to 5.9%: Deloitte digs into what’s fueling Big Pharma’s R&D IRR climb
Recce targets A$15.8M to advance anti-infectives into Phase 3 trials
Vial of Steroid injection with a syringe on black table and stainless steel background.
The true cost of steroid-toxicity 
3D illustration of Palm painful - skeleton x-ray, medical concept.
Q&A: AnaptysBio’s CMO on rosnilimab’s ‘compelling’ phase 2b RA results
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE